The results of various studies from 2010 have underlined the importance of the careful diagnostic assessment of GERD. Recent studies have also provided further evidence of the complex pathogenesis of GERD, and promising agents targeting the underlying factors in the pathogenesis of this condition are in the pipeline, especially for treatment-refractory GERD.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gaddam, S. et al. The impact of pre-endoscopy proton pump inhibitor use on the classification of non-erosive reflux disease and erosive oesophagitis. Aliment. Pharmacol. Ther. 32, 1266–1274 (2010).
Savarino, E. et al. Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. Am. J. Gastroenterol. 105, 1053–1061 (2010).
Fiocca, R. et al. Development of consensus guidelines for the histologic recognition of microscopic esophagitis in patients with gastroesophageal reflux disease: the Esohisto project. Hum. Pathol. 41, 223–231 (2010).
Farre, R. et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut 59, 164–169 (2010).
Fiocca, R. et al. Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial. Am. J. Gastroenterol. 105, 1015–1023 (2010).
Kandulski, A. et al. Proteinase-activated receptor-2 in the pathogenesis of gastroesophageal reflux disease. Am. J. Gastroenterol. 105, 1934–1943 (2010).
Guarino, M. P. et al. Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol. Motil. 22, 746–751, e219 (2010).
Zerbib, F., Keywood, C. & Strabach, G. Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects. Neurogastroenterol. Motil. 22, 859–865, e231 (2010).
Gerson, L. B. et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am. J. Gastroenterol. 105, 1266–1275 (2010).
Boeckxstaens, G. E. et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 139, 409–417 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Kandulski, A., Malfertheiner, P. Diagnosis, novel mechanisms of disease and promising agents. Nat Rev Gastroenterol Hepatol 8, 73–74 (2011). https://doi.org/10.1038/nrgastro.2010.220
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2010.220
